Possible Prediction of the Response of Esophageal Squamous Cell Carcinoma to Neoadjuvant Chemotherapy Based on Gene Expression Profiling

Overview

Journal Oncotarget

Specialty Oncology

Date 2015 Dec 18

PMID 26673820

Citations 16

Authors

Lu-Yan Shen

Hui Wang

Bin Dong

Wan-Pu Yan

Yao Lin

Qi Shi

Ke-Neng Chen

Affiliations

Soon will be listed here.

Abstract

Background: Heterogeneous efficacy of neoadjuvant chemotherapy has led to controversies that have limited its application in clinical practice. Thus, we aimed to identify potential biomarkers predicting esophageal squamous cell carcinoma (ESCC) chemo-responsiveness by gene expression profiling.

Methods: CCK8 assay was used to evaluate the growth inhibitory effect of different concentrations of cisplatin and paclitaxel on the ESCC cell lines EC109, KYSE450, KYSE410, KYSE510, and KYSE150 to differentiate between chemosensitive and chemoresistant cell lines. Gene expression profiling and Real-time PCR were applied to analyze and validate the gene expression differences between chemosensitive and chemoresistant cell lines. IHC was conducted to examine the expression of selected target markers MUC4, MUC13, and MUC20 in 186 ESCC resection samples and the relationships between their expression and tumor regression grade was analyzed. Moreover, RNAi was conducted to instantly block the expression of MUC4, MUC13, and MUC20 to observe their influences on chemo-responsiveness.

Results: EC109 was found to be relatively sensitive to both cisplatin and paclitaxel, while KYSE410 was relatively resistant to cisplatin, KYSE510 was relatively resistant to paclitaxel. Gene expression profiling analysis showed that 2018 genes were differentially expressed in sensitive cell line compared to resistant cell lines. The expression patterns of MUC4, MUC13, MUC20 were validated. Low expression of MUC4 and MUC20 in resection samples was significantly correlated with better TRG. Blockage of MUC20 and MUC13 decreased the drug-resistance capacity and chemosensitivity, respectively.

Conclusions: MUC4 and MUC20 were identified as potential biomarkers for predicting the efficacy of neoadjuvant chemotherapy in ESCC patients.

Citing Articles

Development of Bivalent Aptamer-DNA Carrier-Doxorubicin Conjugates for Targeted Killing of Esophageal Squamous Cell Carcinoma Cells.

Zhang T, Yin K, Niu X, Bai X, Wang Z, Ji M Int J Mol Sci. 2024; 25(14).

PMID: 39063201 PMC: 11276760. DOI: 10.3390/ijms25147959.

MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis.

Wang X, Shi Y, Shi H, Liu X, Liao A, Liu Z J Exp Clin Cancer Res. 2024; 43(1):68.

PMID: 38439082 PMC: 10913264. DOI: 10.1186/s13046-024-02972-6.

High BMP7 expression is associated with poor prognosis in ovarian cancer.

Vasan R, Yadav J, Aiyappa-Maudsley R, Deen S, Storr S, Martin S J Cell Mol Med. 2023; 27(21):3378-3387.

PMID: 37688374 PMC: 10623526. DOI: 10.1111/jcmm.17951.

MUC13 promotes the development of esophageal cancer by upregulating the expression of O-glycan process-related molecules.

Han Y, Chen G, Liu S, Zhou G, Xu X, Zhang H Discov Oncol. 2023; 14(1):123.

PMID: 37395858 PMC: 10317945. DOI: 10.1007/s12672-023-00713-3.

Network and pathway-based analysis of genes associated with esophageal squamous cell carcinoma.

He W, Yuan K, He J, Wang C, Peng L, Han Y Ann Transl Med. 2023; 11(2):102.

PMID: 36819552 PMC: 9929830. DOI: 10.21037/atm-22-6512.

References

Duong C, Greenawalt D, Kowalczyk A, Ciavarella M, Raskutti G, Murray W . Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer. Ann Surg Oncol. 2007; 14(12):3602-9. DOI: 10.1245/s10434-007-9550-1. View

Bafna S, Kaur S, Momi N, Batra S . Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin. Br J Cancer. 2009; 101(7):1155-61. PMC: 2768097. DOI: 10.1038/sj.bjc.6605285. View

Allum W, Stenning S, Bancewicz J, Clark P, Langley R . Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009; 27(30):5062-7. DOI: 10.1200/JCO.2009.22.2083. View

Grimminger P, Vallbohmer D, Hoffmann A, Schulte C, Bollschweiler E, Schneider P . Quantitative analysis of survivin RNA expression in blood as a non-invasive predictor of response to neoadjuvant radiochemotherapy in esophageal cancer. J Surg Oncol. 2009; 100(6):447-51. DOI: 10.1002/jso.21355. View

Maher S, Gillham C, Duggan S, Smyth P, Miller N, Muldoon C . Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Ann Surg. 2009; 250(5):729-37. DOI: 10.1097/SLA.0b013e3181bce7e1. View

Schauer M, Janssen K, Rimkus C, Raggi M, Feith M, Friess H . Microarray-based response prediction in esophageal adenocarcinoma. Clin Cancer Res. 2009; 16(1):330-7. DOI: 10.1158/1078-0432.CCR-09-1673. View

Makino T, Yamasaki M, Miyata H, Yoshioka S, Takiguchi S, Fujiwara Y . p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer. Ann Surg Oncol. 2009; 17(3):804-11. DOI: 10.1245/s10434-009-0786-9. View

Motoori M, Takemasa I, Yamasaki M, Komori T, Takeno A, Miyata H . Prediction of the response to chemotherapy in advanced esophageal cancer by gene expression profiling of biopsy samples. Int J Oncol. 2010; 37(5):1113-20. DOI: 10.3892/ijo_00000763. View

Wen J, Yang H, Liu M, Luo K, Liu H, Hu Y . Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neo-chemoradiotherapy. Ann Oncol. 2014; 25(9):1769-1774. DOI: 10.1093/annonc/mdu201. View

10.

Sohda M, Ishikawa H, Masuda N, Kato H, Miyazaki T, Nakajima M . Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer. 2004; 110(6):838-44. DOI: 10.1002/ijc.20215. View

11.

Warnecke-Eberz U, Metzger R, Miyazono F, Baldus S, Neiss S, Brabender J . High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res. 2004; 10(11):3794-9. DOI: 10.1158/1078-0432.CCR-03-0079. View

12.

Ringel J, Lohr M . The MUC gene family: their role in diagnosis and early detection of pancreatic cancer. Mol Cancer. 2003; 2:9. PMC: 149423. View

13.

Mandard A, Dalibard F, MANDARD J, Marnay J, Henry-Amar M, Petiot J . Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994; 73(11):2680-6. DOI: 10.1002/1097-0142(19940601)73:11<2680::aid-cncr2820731105>3.0.co;2-c. View

14.

Kelsen D, Ginsberg R, Pajak T, Sheahan D, Gunderson L, Mortimer J . Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998; 339(27):1979-84. DOI: 10.1056/NEJM199812313392704. View

15.

Yamamoto M, Tsujinaka T, Shiozaki H, Doki Y, Tamura S, Inoue M . Metallothionein expression correlates with the pathological response of patients with esophageal cancer undergoing preoperative chemoradiation therapy. Oncology. 1999; 56(4):332-7. DOI: 10.1159/000011988. View

16.

Luthra R, Wu T, Luthra M, Izzo J, Lopez-Alvarez E, Zhang L . Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol. 2005; 24(2):259-67. DOI: 10.1200/JCO.2005.03.3688. View

17.

Kang S, Han J, Lee K, Choi J, Park J, Kim H . Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy. Clin Cancer Res. 2007; 13(14):4146-53. DOI: 10.1158/1078-0432.CCR-06-3063. View

18.

Kelsen D, Winter K, Gunderson L, Mortimer J, Estes N, Haller D . Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007; 25(24):3719-25. DOI: 10.1200/JCO.2006.10.4760. View

19.

Gotoh M, Takiuchi H, Kawabe S, Ohta S, Kii T, Kuwakado S . Epidermal growth factor receptor is a possible predictor of sensitivity to chemoradiotherapy in the primary lesion of esophageal squamous cell carcinoma. Jpn J Clin Oncol. 2007; 37(9):652-7. DOI: 10.1093/jjco/hym089. View

20.

Samejima R, Kitajima Y, Yunotani S, Miyazaki K . Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma. Anticancer Res. 2000; 19(6C):5515-21. View